Erytech Pharma SA Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Erytech Pharma SA prevailing Real Value cannot be determined due to lack of data. The current price of Erytech Pharma SA is $0.0. Our model computes the value of Erytech Pharma SA from reviewing the firm fundamentals such as Shares Outstanding of 34.12 M, profit margin of (0.03) %, and Current Valuation of 211.16 K as well as analyzing its technical indicators and probability of bankruptcy.
Erytech Pharma Total Value Analysis
Erytech Pharma SA is currently anticipated to have valuation of 211.16 K with market capitalization of 29.57 M, debt of 13.57 M, and cash on hands of 54.05 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Erytech Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
211.16 K | 29.57 M | 13.57 M | 54.05 M |
Erytech Pharma Asset Utilization
One of the ways to look at asset utilization of Erytech is to check how much profit was generated for every dollar of assets it reports. Erytech Pharma SA shows a negative utilization of assets of -0.3 percent, losing $0.003014 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Erytech Pharma SA shows how discouraging it operates for each dollar spent on its assets.Erytech Pharma Ownership Allocation
Erytech Pharma holds a total of 34.12 Million outstanding shares. Roughly 92.35 percent of Erytech Pharma outstanding shares are held by general public with 7.65 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Erytech Pharma Profitability Analysis
Net Loss for the year was (228 K) with profit before overhead, payroll, taxes, and interest of 4.18 M.Erytech Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Erytech Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 31 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |